Clinical trials: Nevirapine
HIV Infections
The Safety and Effectiveness of Nevirapine Plus Lamivudine Plus Other Anti-HIV Drugs
To evaluate the tolerance, safety, and effectiveness of Viramune in preventing clinical AIDS progression events or death when used in combination with Lamivudine and background nucleoside therapy.
- Trial name
- NCT00002368
- Testing
- Nevirapine, Lamivudine
- Where
- 53 sites in United States
- Volunteers
- 2,000 people
- Sponsor
- Boehringer Ingelheim
Healthy
Pharmacoscintigraphic Investigation Into the Absorption of Nevirapine When Released Into Different Parts of the Gastro-intestinal Tract in Healthy Males
Study to determine the absorption of Nevirapine from different regions of the Gastro Intestinal tract.
- Trial name
- NCT02191189
- Testing
- Nevirapine suspension, into Enterion™ capsule, Nevirapine suspension
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
HIV Infections
The Safety and Effectiveness of Nevirapine and Zidovudine, Given Separately and Together, in HIV-1 Infected Patients Who Have No Symptoms of the Disease
PRIMARY: To compare the effect of nevirapine versus placebo alone or in combination with zidovudine (AZT) on CD4 T-cell count and percentage after 3 and 6 months of treatment.
- Trial name
- NCT00002324
- Testing
- Nevirapine, Zidovudine
- Where
- 18 sites in United States
- Volunteers
- 250 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine, Abacavir and Amprenavir in HIV-1 Infected Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Naive Adults
Study to determine the effects of 28 days of nevirapine treatment on the steady-state pharmacokinetics of amprenavir and of abacavir and to further evaluate the pharmacokinetics of nevirapine in combination with amprenavir and…
- Trial name
- NCT02182765
- Testing
- Nevirapine, Amprenavir, Abacavir
- Volunteers
- 8 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Study to Determine the Effects of Nevirapine (VIRAMUNE®) on the Steady State Pharmacokinetics of Rifabutin (MYCOBUTIN®) in HIV+ Patients
Study to determine the effects of nevirapine on the steady state pharmacokinetics of rifabutin and to assess the steady state pharmacokinetics of nevirapine when given in combination with rifabutin
- Trial name
- NCT02184078
- Testing
- Nevirapine, Rifabutin
- Volunteers
- 19 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Long-term Study in Patients Under Anti-retroviral Combination Therapy Switching to Viramune®
Collecting data on maintaining anti-retroviral activity (quantitative HIV RNA determination) and immunological activity (CD4 cells) after switching from protease inhibitor or NNRTI to Nevirapine (Viramune®) and collecting of…
- Trial name
- NCT02191293
- Testing
- Viramune® tablets
- Volunteers
- 228 people
- Sponsor
- Boehringer Ingelheim
HIV Infections, Metabolism, Lipids
An Open-label, Non-randomized, Single-arm Study to Investigate the Mechanism(s) by Which Nevirapine Increases Plasma HDL in HIV+ Subjects
1. In order to obtain further insight as to how NVP affects HDL metabolism, the in vivo kinetics of the HDL apolipoprotein, Apo A-1, before and 6 weeks after initiation of NVP containing treatment were evaluated.
- Trial name
- NCT00144261
- Testing
- nevirapine
- Where
- 3 sites in Netherlands, United Kingdom
- Volunteers
- 15 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)
To evaluate changes in renal function, efficacy, and safety when switching from a combination of tenofovir/emtricitabine (TDF/FTC) plus a protease inhibitor/ritonavir (PI/r) to a combination of raltegravir (MK-0518) plus…
- Trial name
- RANIA (NCT02116660)
- Testing
- Raltegravir (MK-0518), Nevirapine, Lamivudine
- Volunteers
- 11 people
- Sponsor
- Merck Sharp & Dohme LLC
HIV-1
Multiple Dose BE Study With Nevirapine 400mg PR Tablets
The objective of this steady state pivotal study is to compare the rate and extent of absorption and to evaluate Bioequivalence of test drug compared to the approved reference product in HIV infected individuals
- Trial name
- NCT02202005
- Testing
- Nevirapine, Viramune®
- Where
- United Kingdom
- Volunteers
- 46 people
- Sponsor
- Ratiopharm GmbH
HIV Infections
The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine
To determine the potential effects of 28 days of nevirapine treatment on the steady-state pharmacokinetics of nelfinavir and of stavudine (d4T), and to further evaluate the pharmacokinetics of nevirapine in combination with…
- Trial name
- NCT00002381
- Testing
- Nelfinavir mesylate, Nevirapine, Stavudine
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
ATV/Ritonavir Nevirapine Interaction (USPAC)
Open-Label, multiple-dose, drug interaction study to assess the effect of nevirapine on the pharmacokinetics of atazanavir in HIV-infected individuals.
- Trial name
- NCT00162149
- Testing
- Nevirapine, Nevirapine + Atazanavir/Ritonavir, Atazanavir + Ritonavir
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Impact of Switching to NNRTI-based Therapy on the Quality of Life of HIV-infected Patients With Virological Suppression
Observational study to evaluate therapeutic switch to a NNRTI-based regimen on quality of life of HIV-positive patients
- Trial name
- NCT02191202
- Testing
- Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTI)
- Volunteers
- 283 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment
The purpose of this study is to compare the safety and effectiveness of 2 anti-HIV drug combinations in HIV-infected patients. Both combinations will include nevirapine (NVP), 2 nucleoside reverse transcriptase inhibitors…
- Trial name
- NCT00004581
- Testing
- Lopinavir/Ritonavir, Nevirapine
- Where
- 88 sites in United States, Australia and 12 more
- Volunteers
- 300 people
- Sponsor
- Abbott
Acquired Immunodeficiency Syndrome
Open Label Study of NVP+CBV Treatment in Women Who Have Received sdNVP for the pMTCT of HIV
To determine the response to treatment with NVP, ZDV and 3TC in HIV positive women, who previously received NVP for the prevention of mother to child transmission.
- Trial name
- NCT00144157
- Testing
- Nevirapine, Zidovudine, 3TC
- Where
- 3 sites in South Africa
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Investigation of the Potential Pharmacokinetic Interaction Between Nevirapine (VIRAMUNE) and Ethinyl Estradiol/Norethindrone in HIV-1 Infected Women
Study to determine the effects of nevirapine treatment on the pharmacokinetics of ethinyl estradiol (EE)/norethindrone (NET).
- Trial name
- NCT02182791
- Testing
- Nevirapine, EE/NET
- Volunteers
- 14 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
PMS Assessing the Long-term Efficacy and Safety of Nevirapine Therapy (Combined With Other ARV Drugs) in HIV-1 Positive Patients in Daily Clinical Practice.
The aim of this trial is to evaluate the safety and virological and immunological efficacy of Viramune® on a background of different antiretroviral drug combinations.
- Trial name
- NCT00736502
- Where
- 17 sites in Austria, Poland
- Volunteers
- 280 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Effects of Nevirapine on the Steady State Pharmacokinetics of Fluconazole in HIV Positive Patients
The purpose of this study was to determine the effects of nevirapine on the steady state pharmacokinetics of fluconazole and to assess the steady-state pharmacokinetics of nevirapine when given in combination with fluconazole.
- Trial name
- NCT02181946
- Testing
- Fluconazole, Nevirapine
- Volunteers
- 24 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
TMC207-TiDP13-C117: Interaction Study in Human Immunodeficiency Virus-type 1 (HIV-1) Infected Patients With Nevirapine (NVP)
The purpose of this Phase I, open-label, single sequence drug-drug interaction trial in human immunodeficiency virus-type 1 infected patients is to investigate the potential interaction between steady-state nevirapine (NVP) 200…
- Trial name
- NCT00910806
- Testing
- TMC207; nevirapine
- Where
- South Africa
- Volunteers
- 16 people
- Sponsor
- Tibotec BVBA
HIV Infections
An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)
To assess the safety and tolerance of multiple oral doses of nevirapine in combination with zidovudine (AZT); to get information on the pharmacokinetics (blood levels) and dose proportionality of nevirapine/AZT with multiple…
- Trial name
- NCT00000649
- Testing
- Nevirapine, Zidovudine
- Where
- 3 sites in United States
- Volunteers
- 30 people
- Sponsor
- Boehringer Ingelheim
HIV Infections
Observational Study With Antiretroviral Treated Patients Switching to Nevirapine Plus Two Nucleoside Reverse Transcriptase Inhibitor (NRTI) Regimens
Collecting data on maintaining anti-retroviral activity (quantitative HIV RNA determination) and immunological activity (CD4 cells) after switching from protease inhibitor or NNRTI to Nevirapine (Viramune®) and collecting of…
- Trial name
- NCT02191319
- Testing
- Viramune®
- Volunteers
- 55 people
- Sponsor
- Boehringer Ingelheim